- Home
- CTOR vs XTNT Comparison
CTOR vs XTNT Comparison
Compare CTOR & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTOR
- XTNT
- Stock Information
- Founded
- CTOR 2021
- XTNT N/A
- Country
- CTOR United States
- XTNT United States
- Employees
- CTOR N/A
- XTNT N/A
- Industry
- CTOR
- XTNT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CTOR
- XTNT Health Care
- Exchange
- CTOR NYSE
- XTNT Nasdaq
- Market Cap
- CTOR 63.7M
- XTNT 60.9M
- IPO Year
- CTOR N/A
- XTNT N/A
- Fundamental
- Price
- CTOR $5.05
- XTNT $0.62
- Analyst Decision
- CTOR Buy
- XTNT
- Analyst Count
- CTOR 2
- XTNT 0
- Target Price
- CTOR $6.00
- XTNT N/A
- AVG Volume (30 Days)
- CTOR 3.1M
- XTNT 48.4K
- Earning Date
- CTOR 08-11-2025
- XTNT 08-07-2025
- Dividend Yield
- CTOR N/A
- XTNT N/A
- EPS Growth
- CTOR N/A
- XTNT N/A
- EPS
- CTOR N/A
- XTNT N/A
- Revenue
- CTOR N/A
- XTNT $122,298,000.00
- Revenue This Year
- CTOR N/A
- XTNT $11.64
- Revenue Next Year
- CTOR N/A
- XTNT $7.59
- P/E Ratio
- CTOR N/A
- XTNT N/A
- Revenue Growth
- CTOR N/A
- XTNT 20.81
- 52 Week Low
- CTOR $0.55
- XTNT $0.33
- 52 Week High
- CTOR $49.00
- XTNT $0.83
- Technical
- Relative Strength Index (RSI)
- CTOR N/A
- XTNT 48.39
- Support Level
- CTOR N/A
- XTNT $0.57
- Resistance Level
- CTOR N/A
- XTNT $0.65
- Average True Range (ATR)
- CTOR 0.00
- XTNT 0.05
- MACD
- CTOR 0.00
- XTNT -0.01
- Stochastic Oscillator
- CTOR 0.00
- XTNT 33.33
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
About XTNT Xtant Medical Holdings Inc.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.